JAK2 and myeloproliferative neoplasm: However, not all these patients develop Ph- MPNs, and thus it may be difficult to distinguish patients with Ph- MPN and low allelic burden and healthy patients with low-level JAK2 V617F mutations without any known clinical significance [102].